Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ORLANDO PUENTE

NPI
1811976459
CMS profile
1289288
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$360.71

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $360.71 7

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Surmodics, Inc. $360.71 7

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ORLANDO PUENTE

NPI 1811976459 · CMS profile ID 1289288

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811976459?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ORLANDO PUENTE, NPI 1811976459, CMS profile ID 1289288. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811976459?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ORLANDO PUENTE, NPI 1811976459, CMS profile ID 1289288. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811976459?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ORLANDO PUENTE, NPI 1811976459, CMS profile ID 1289288, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1811976459?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $360.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Surmodics, Inc. $71.8211/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954502435 CMS
Surmodics, Inc. $20.9310/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954502423 CMS
Surmodics, Inc. $43.0809/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954502413 CMS
Surmodics, Inc. $49.6009/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954502403 CMS
Surmodics, Inc. $21.7507/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954502391 CMS
Surmodics, Inc. $47.7806/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954502381 CMS
Surmodics, Inc. $105.7505/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954502371 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $369.99 5
PY2020 $152.98 2
PY2021 $110.70 1
PY2022 $360.71 7
PY2023 $102.32 1
PY2025 $123.92 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,200.00 1
PY2025 Principal investigator $2,235,212.65 131
PY2024 Recipient $6,424.00 1
PY2024 Principal investigator $2,519,821.99 65
PY2023 Recipient $300.00 1
PY2023 Principal investigator $2,960,886.91 78
PY2022 Recipient $803.00 1
PY2022 Principal investigator $3,163,802.40 54
PY2021 Recipient $244,761.00 2
PY2021 Principal investigator $701,141.03 18
PY2020 Principal investigator $312,360.32 152
PY2019 Principal investigator $247,110.23 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

132 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $8,464.61 12/23/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228815676
Principal investigator 1 PFIZER INC. $22,975.37 12/17/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228815622
Principal investigator 1 ModernaTX, Inc. $5,110.38 12/16/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985782
Principal investigator 1 ModernaTX, Inc. $12,113.88 12/16/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985832
Principal investigator 1 PFIZER INC. $3,042.00 12/12/2025 Non-covered Recipient Entity
Institute LLC Miami Dade Medical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228805857
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/11/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985810
Principal investigator 1 Eli Lilly and Company $1,000.00 12/01/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE LLC
Not supplied No dispute reported 06/30/2026 1187886724
Principal investigator 1 ModernaTX, Inc. $51,483.99 11/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985728
Principal investigator 1 ModernaTX, Inc. $4,140.36 11/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985820
Principal investigator 1 ModernaTX, Inc. $5,703.72 11/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985856
Principal investigator 1 PFIZER INC. $55,624.58 11/27/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228818196
Principal investigator 1 PFIZER INC. $68,978.04 11/26/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228817736
Principal investigator 1 PFIZER INC. $1,209.23 11/20/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228818138
Principal investigator 1 PFIZER INC. $13,689.31 11/15/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228818190
Principal investigator 1 PFIZER INC. $29,021.52 11/11/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228817793
Principal investigator 1 ModernaTX, Inc. $923.00 11/05/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985794
Principal investigator 1 PFIZER INC. $2,651.33 10/30/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228824724
Principal investigator 1 ModernaTX, Inc. $5,072.10 10/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985792
Principal investigator 1 ModernaTX, Inc. $2,760.24 10/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985844
Principal investigator 1 PFIZER INC. $19,347.68 10/11/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228825214
Principal investigator 1 ModernaTX, Inc. $1,058.89 09/29/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985750
Principal investigator 1 ModernaTX, Inc. $13,801.20 09/29/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985774
Principal investigator 1 ModernaTX, Inc. $787.31 09/29/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985830
Principal investigator 1 ModernaTX, Inc. $5,569.74 09/29/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985836
Principal investigator 1 ModernaTX, Inc. $3,030.57 09/29/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985852
Principal investigator 1 PFIZER INC. $26,603.06 09/27/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228835954
Principal investigator 1 PFIZER INC. $43,243.48 09/24/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228836026
Principal investigator 1 ModernaTX, Inc. $923.00 09/15/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985812
Principal investigator 1 PFIZER INC. $31,439.98 09/09/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228836013
Principal investigator 1 ModernaTX, Inc. $17,021.48 08/28/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985766
Principal investigator 1 ModernaTX, Inc. $5,818.56 08/28/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985802
Principal investigator 1 ModernaTX, Inc. $8,471.12 08/28/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985806
Principal investigator 1 PFIZER INC. $2,418.46 08/21/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228843334
Principal investigator 1 PFIZER INC. $3,841.59 08/05/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228843340
Principal investigator 1 PFIZER INC. $99,156.86 08/01/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228843286
Principal investigator 1 ModernaTX, Inc. $2,117.78 07/29/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985730
Principal investigator 1 ModernaTX, Inc. $460.04 07/29/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985758
Principal investigator 1 ModernaTX, Inc. $1,416.36 07/29/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985764
Principal investigator 1 ModernaTX, Inc. $787.31 07/29/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985780
Principal investigator 1 PFIZER INC. $27,389.19 07/26/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228848275
Principal investigator 1 PFIZER INC. $15,719.99 07/11/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228848267
Principal investigator 1 PFIZER INC. $213,436.76 07/08/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228848211
Principal investigator 1 PFIZER INC. $1,345.50 07/02/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228848203
Principal investigator 1 ModernaTX, Inc. $4,229.94 06/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985734
Principal investigator 1 ModernaTX, Inc. $5,520.48 06/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985842
Principal investigator 1 ModernaTX, Inc. $787.31 06/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985848
Principal investigator 1 ModernaTX, Inc. $4,235.56 06/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985850
Principal investigator 1 PFIZER INC. $41,662.20 06/26/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228851573
Principal investigator 1 PFIZER INC. $17,187.90 06/21/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228851583
Principal investigator 1 ModernaTX, Inc. $38,120.04 06/18/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985808
Principal investigator 1 ModernaTX, Inc. $5,761.14 06/18/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985824
Principal investigator 1 ModernaTX, Inc. $9,660.84 06/18/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985828
Principal investigator 1 PFIZER INC. $38,023.90 06/14/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228851514
Principal investigator 1 PFIZER INC. $106,514.04 06/10/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228851591
Principal investigator 1 PFIZER INC. $12,990.30 05/30/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228857689
Principal investigator 1 ModernaTX, Inc. $5,895.12 05/28/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985756
Principal investigator 1 ModernaTX, Inc. $24,382.12 05/28/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985762
Principal investigator 1 ModernaTX, Inc. $34,943.37 05/28/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985770
Principal investigator 1 PFIZER INC. $145.22 05/27/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707754
Principal investigator 1 PFIZER INC. $145.22 05/27/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228841240
Principal investigator 1 PFIZER INC. $10,412.97 05/23/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228857694
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228706741
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228708110
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228840974
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228841004
Principal investigator 1 PFIZER INC. $69,189.75 05/15/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228857737
Principal investigator 1 ModernaTX, Inc. $1,500.00 05/14/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985786
Principal investigator 1 PFIZER INC. $31,681.09 05/08/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228857648
Principal investigator 1 PFIZER INC. $3,444.29 05/01/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228857681
Principal investigator 1 ModernaTX, Inc. $700.00 04/28/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985746
Principal investigator 1 ModernaTX, Inc. $40,023.48 04/28/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985748
Principal investigator 1 ModernaTX, Inc. $10,000.00 04/28/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985814
Principal investigator 1 ModernaTX, Inc. $5,665.44 04/28/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985816
Principal investigator 1 ModernaTX, Inc. $2,000.00 04/28/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985818
Principal investigator 1 PFIZER INC. $2,480.90 04/25/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228857642
Principal investigator 1 ModernaTX, Inc. $530.40 04/24/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985772
Principal investigator 1 ModernaTX, Inc. $63.70 04/23/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985736
Principal investigator 1 ModernaTX, Inc. $65.00 04/23/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985742
Principal investigator 1 ModernaTX, Inc. $61.10 04/23/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985790
Principal investigator 1 ModernaTX, Inc. $690.00 04/16/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985826
Principal investigator 1 ModernaTX, Inc. $2,749.50 04/16/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985840
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,500.00 04/04/2025 Non-covered Recipient Entity
Advarra
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235999239
Principal investigator 1 ModernaTX, Inc. $8,027.50 04/01/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985738
Principal investigator 1 PFIZER INC. $13,522.47 03/28/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228860770
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $50,955.00 03/26/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235995747
Principal investigator 1 ModernaTX, Inc. $787.31 03/25/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985788
Principal investigator 1 ModernaTX, Inc. $10,460.40 03/25/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985796
Principal investigator 1 ModernaTX, Inc. $34,963.04 03/25/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985838
Principal investigator 1 ModernaTX, Inc. $5,435.76 03/25/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985846
Principal investigator 1 PFIZER INC. $189.80 03/24/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707930
Principal investigator 1 PFIZER INC. $189.80 03/23/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228841201
Principal investigator 1 PFIZER INC. $23,124.43 03/22/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228862921
Principal investigator 1 PFIZER INC. $47,049.03 03/20/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228860812
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707932
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228841191
Principal investigator 1 PFIZER INC. $13,685.00 03/04/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228860801
Principal investigator 1 ModernaTX, Inc. $1,111.50 03/03/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985834
Principal investigator 1 ModernaTX, Inc. $6,909.54 02/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985752
Principal investigator 1 ModernaTX, Inc. $1,525.22 02/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985760
Principal investigator 1 ModernaTX, Inc. $2,526.48 02/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985768
Principal investigator 1 ModernaTX, Inc. $30,305.70 02/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985776
Principal investigator 1 ModernaTX, Inc. $41,863.64 02/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985822
Principal investigator 1 ModernaTX, Inc. $8,368.32 02/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985854
Recipient PFIZER INC. $3,200.00 02/27/2025 Covered Recipient Physician NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838819
Principal investigator 1 ModernaTX, Inc. $386.10 02/20/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985754
Principal investigator 1 ModernaTX, Inc. $1,900.00 02/19/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985798
Principal investigator 1 PFIZER INC. $248.40 02/19/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228835963
Principal investigator 1 PFIZER INC. $99,051.57 02/12/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228836019
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $63,135.00 02/11/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235995743
Principal investigator 1 PFIZER INC. $726.10 02/10/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707856
Principal investigator 1 PFIZER INC. $317.00 02/10/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707934
Principal investigator 1 PFIZER INC. $726.10 02/10/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228840998
Principal investigator 1 PFIZER INC. $317.00 02/10/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228841197
Principal investigator 1 PFIZER INC. $2,350.00 02/08/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707858
Principal investigator 1 PFIZER INC. $2,087.25 02/05/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228835968
Principal investigator 1 PFIZER INC. $981.24 02/03/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228814908
Principal investigator 1 PFIZER INC. $837.08 02/03/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228815077
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $870.98 01/27/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235995745
Principal investigator 1 Eli Lilly and Company $2,739.00 01/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187884264
Principal investigator 1 ModernaTX, Inc. $3,050.44 01/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985732
Principal investigator 1 ModernaTX, Inc. $15,690.60 01/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985740
Principal investigator 1 ModernaTX, Inc. $20,701.80 01/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985744
Principal investigator 1 ModernaTX, Inc. $4,713.74 01/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985778
Principal investigator 1 ModernaTX, Inc. $2,028.84 01/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985784
Principal investigator 1 ModernaTX, Inc. $2,966.70 01/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985800
Principal investigator 1 ModernaTX, Inc. $787.31 01/27/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985804
Principal investigator 1 PFIZER INC. $14,318.77 01/25/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228863294
Principal investigator 1 PFIZER INC. $20,530.95 01/22/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228863311
Principal investigator 1 PFIZER INC. $9,786.85 01/15/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228863303
Principal investigator 1 PFIZER INC. $541.50 01/09/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228863359
Principal investigator 1 Eli Lilly and Company $166,093.62 01/07/2025 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187885500
Principal investigator 1 PFIZER INC. $122,134.10 01/01/2025 Non-covered Recipient Entity
Miami Dade Medical Research Institute LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228863318